Literature DB >> 11216933

Tolerance of efavirenz in children.

J P Teglas1, P Quartier, J M Treluyer, M Burgard, V Gregoire, S Blanche.   

Abstract

OBJECTIVE: To extend the limited knowledge of efavirenz tolerance in children.
METHOD: An observational study of 33 children given efavirenz combined with various others agents and followed in a single institution.
RESULTS: Fifteen (42%) of the children presented at least one clinically discernable side effect, cutaneous (n = 5), nervous system (n = 10), or both (n = 2). Intolerance led to treatment interruption in seven children but the main symptom was transitory dizziness or other signs similar to those observed in adults.
CONCLUSION: Early, often transient nervous system side effects require careful preparation with the child and his family to avoid premature and inadequate withdrawal from treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11216933     DOI: 10.1097/00002030-200101260-00014

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  Absence seizures associated with efavirenz initiation.

Authors:  Renate Strehlau; Leigh Martens; Ashraf Coovadia; Collet Dandara; Jennifer Norman; Julia Maisel; Louise Kuhn; Elaine J Abrams
Journal:  Pediatr Infect Dis J       Date:  2011-11       Impact factor: 2.129

Review 2.  Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.

Authors:  Martina Penazzato; Carlo Giaquinto
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

Review 3.  The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection.

Authors:  S Maddocks; D Dwyer
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.

Authors:  Elizabeth Peacock-Villada; Barbra A Richardson; Grace C John-Stewart
Journal:  Pediatrics       Date:  2011-01-24       Impact factor: 7.124

Review 5.  Efavirenz in the therapy of HIV infection.

Authors:  Natella Y Rakhmanina; John N van den Anker
Journal:  Expert Opin Drug Metab Toxicol       Date:  2010-01       Impact factor: 4.481

6.  24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.

Authors:  H Hien; N Meda; S Diagbouga; E Zoure; S Yaméogo; H Tamboura; J Somé; A Ouiminga; F Rouet; A Drabo; A Hien; J Nicolas; H Chappuy; P Van de Perre; P Msellati; B Nacro
Journal:  Afr Health Sci       Date:  2013-06       Impact factor: 0.927

Review 7.  Current and future antiretroviral treatment options in paediatric HIV infection.

Authors:  Carlo Giaquinto; Erika Morelli; Federica Fregonese; Osvalda Rampon; Martina Penazzato; Anita de Rossi; Ruggero D'Elia
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

8.  AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

Authors:  Hadija H Semvua; Gibson S Kibiki
Journal:  BMC Res Notes       Date:  2011-11-24

9.  Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.

Authors:  Beatriz Larru; Jessica Eby; Elizabeth D Lowenthal
Journal:  Pediatric Health Med Ther       Date:  2014-05-29

10.  Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.

Authors:  Janneke H van Dijk; Catherine G Sutcliffe; Francis Hamangaba; Christopher Bositis; Douglas C Watson; William J Moss
Journal:  PLoS One       Date:  2013-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.